Trial Profile
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-MM4
- Sponsors Takeda Development Center Americas; Takeda Oncology
- 23 Aug 2023 Time frame of primary endpoint has been changed from randomization until PD or death (up to 52 months).
- 01 Jul 2023 Results of a sub-group analysis assessing safety and efficacy sub-grouped by age and frailty status published in the Clinical Lymphoma, Myeloma & Leukemia
- 25 Apr 2023 Results of exposure-response Analysis of the TOURMALINE-MM4 Study published in the Clinical Pharmacology and Therapeutics